Chemotherapy in elderly patients with nonsmall cell lung cancer

Rajwanth R. Veluswamy, Benjamin Levy, Juan P. Wisnivesky

Research output: Contribution to journalReview article

Abstract

Purpose of review: Using chemotherapy in elderly nonsmall cell lung cancer (NSCLC) patients is often challenging given concerns of treatment-related toxicity. However, data have demonstrated that chemotherapy can lead to improved survival in this age group. In this review, we summarize existing data and discuss the role of chemotherapy in elderly patients with localized, locally advanced, and metastatic NSCLC. Recent findings: Clear evidence-based guidelines for chemotherapy management in elderly patients is lacking given the limited prospective data available. However, there are more clinical trials investigating optimal chemotherapy agents and dosing schedules specific to the elderly. Comprehensive geriatric assessment-directed interventions are also being prospectively investigated to improve treatment selection for elderly patients. Summary: Chronological age should not be a limiting factor for chemotherapy use in elderly NSCLC patients. Several studies have demonstrated similar survival benefits than in younger patients when chemotherapy is given as adjuvant treatment for localized disease; part of definitive treatment with radiation in locally advanced disease; and palliative treatment for advanced NSCLC, however, at the cost of greater toxicity. Tolerability of chemotherapy in this heterogeneous group can be difficult to predict. Therefore, therapeutic decisions should be individualized based on performance status. Comprehensive geriatric assessment should be used to supplement performance status measures to minimize both under and overtreatment.

Original languageEnglish (US)
Pages (from-to)336-343
Number of pages8
JournalCurrent Opinion in Pulmonary Medicine
Volume22
Issue number4
DOIs
StatePublished - Jul 1 2016
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Geriatric Assessment
Therapeutics
Survival
Palliative Care
Patient Selection
Appointments and Schedules
Age Groups
Clinical Trials
Guidelines
Radiation

Keywords

  • advanced disease
  • chemotherapy
  • elderly
  • nonsmall cell lung cancer
  • treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Chemotherapy in elderly patients with nonsmall cell lung cancer. / Veluswamy, Rajwanth R.; Levy, Benjamin; Wisnivesky, Juan P.

In: Current Opinion in Pulmonary Medicine, Vol. 22, No. 4, 01.07.2016, p. 336-343.

Research output: Contribution to journalReview article

Veluswamy, Rajwanth R. ; Levy, Benjamin ; Wisnivesky, Juan P. / Chemotherapy in elderly patients with nonsmall cell lung cancer. In: Current Opinion in Pulmonary Medicine. 2016 ; Vol. 22, No. 4. pp. 336-343.
@article{ab6e1fea0d8a4630bf5153a168b81e62,
title = "Chemotherapy in elderly patients with nonsmall cell lung cancer",
abstract = "Purpose of review: Using chemotherapy in elderly nonsmall cell lung cancer (NSCLC) patients is often challenging given concerns of treatment-related toxicity. However, data have demonstrated that chemotherapy can lead to improved survival in this age group. In this review, we summarize existing data and discuss the role of chemotherapy in elderly patients with localized, locally advanced, and metastatic NSCLC. Recent findings: Clear evidence-based guidelines for chemotherapy management in elderly patients is lacking given the limited prospective data available. However, there are more clinical trials investigating optimal chemotherapy agents and dosing schedules specific to the elderly. Comprehensive geriatric assessment-directed interventions are also being prospectively investigated to improve treatment selection for elderly patients. Summary: Chronological age should not be a limiting factor for chemotherapy use in elderly NSCLC patients. Several studies have demonstrated similar survival benefits than in younger patients when chemotherapy is given as adjuvant treatment for localized disease; part of definitive treatment with radiation in locally advanced disease; and palliative treatment for advanced NSCLC, however, at the cost of greater toxicity. Tolerability of chemotherapy in this heterogeneous group can be difficult to predict. Therefore, therapeutic decisions should be individualized based on performance status. Comprehensive geriatric assessment should be used to supplement performance status measures to minimize both under and overtreatment.",
keywords = "advanced disease, chemotherapy, elderly, nonsmall cell lung cancer, treatment",
author = "Veluswamy, {Rajwanth R.} and Benjamin Levy and Wisnivesky, {Juan P.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1097/MCP.0000000000000286",
language = "English (US)",
volume = "22",
pages = "336--343",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Chemotherapy in elderly patients with nonsmall cell lung cancer

AU - Veluswamy, Rajwanth R.

AU - Levy, Benjamin

AU - Wisnivesky, Juan P.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Purpose of review: Using chemotherapy in elderly nonsmall cell lung cancer (NSCLC) patients is often challenging given concerns of treatment-related toxicity. However, data have demonstrated that chemotherapy can lead to improved survival in this age group. In this review, we summarize existing data and discuss the role of chemotherapy in elderly patients with localized, locally advanced, and metastatic NSCLC. Recent findings: Clear evidence-based guidelines for chemotherapy management in elderly patients is lacking given the limited prospective data available. However, there are more clinical trials investigating optimal chemotherapy agents and dosing schedules specific to the elderly. Comprehensive geriatric assessment-directed interventions are also being prospectively investigated to improve treatment selection for elderly patients. Summary: Chronological age should not be a limiting factor for chemotherapy use in elderly NSCLC patients. Several studies have demonstrated similar survival benefits than in younger patients when chemotherapy is given as adjuvant treatment for localized disease; part of definitive treatment with radiation in locally advanced disease; and palliative treatment for advanced NSCLC, however, at the cost of greater toxicity. Tolerability of chemotherapy in this heterogeneous group can be difficult to predict. Therefore, therapeutic decisions should be individualized based on performance status. Comprehensive geriatric assessment should be used to supplement performance status measures to minimize both under and overtreatment.

AB - Purpose of review: Using chemotherapy in elderly nonsmall cell lung cancer (NSCLC) patients is often challenging given concerns of treatment-related toxicity. However, data have demonstrated that chemotherapy can lead to improved survival in this age group. In this review, we summarize existing data and discuss the role of chemotherapy in elderly patients with localized, locally advanced, and metastatic NSCLC. Recent findings: Clear evidence-based guidelines for chemotherapy management in elderly patients is lacking given the limited prospective data available. However, there are more clinical trials investigating optimal chemotherapy agents and dosing schedules specific to the elderly. Comprehensive geriatric assessment-directed interventions are also being prospectively investigated to improve treatment selection for elderly patients. Summary: Chronological age should not be a limiting factor for chemotherapy use in elderly NSCLC patients. Several studies have demonstrated similar survival benefits than in younger patients when chemotherapy is given as adjuvant treatment for localized disease; part of definitive treatment with radiation in locally advanced disease; and palliative treatment for advanced NSCLC, however, at the cost of greater toxicity. Tolerability of chemotherapy in this heterogeneous group can be difficult to predict. Therefore, therapeutic decisions should be individualized based on performance status. Comprehensive geriatric assessment should be used to supplement performance status measures to minimize both under and overtreatment.

KW - advanced disease

KW - chemotherapy

KW - elderly

KW - nonsmall cell lung cancer

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84964389453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964389453&partnerID=8YFLogxK

U2 - 10.1097/MCP.0000000000000286

DO - 10.1097/MCP.0000000000000286

M3 - Review article

C2 - 27100301

AN - SCOPUS:84964389453

VL - 22

SP - 336

EP - 343

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 4

ER -